Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
Official title: Unraveling the Mechanisms of Cyclin D1-Induced Replication Stress and DNA Damage Repair Dependencies in Mantle Cell Lymphoma: A Path to Novel Therapeutic Strategies for High-Risk Disease
Funded at Mayo Clinic Rochester · NIH-11451705 · Data updated 2026-11-12
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 6, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $324,272 |
| NIH project number | 1K08CA308863-01A1 |
| Project ID | NIH-11451705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with mantle cell lymphoma, especially high-risk or relapsed cases, who may be eligible for future translational trials.
✕Less likely to help
Patients without mantle cell lymphoma or those not matching high-risk/relapsed criteria may not benefit.
What this research studies
This grant supports a clinician-investigator in gaining hands-on molecular biology skills related to DNA replication and early-phase clinical trial design. The research tests whether Cyclin D1 overexpression creates replication stress and dependence on a specific DNA repair pathway, and whether inhibiting that pathway could fight mantle cell lymphoma. The project also investigates combinations that simultaneously block multiple DNA repair and stress response mechanisms to enhance anti-tumor effects. Through mentorship and lab training, the team aims to translate these insights into novel therapeutic strategies for patients with high-risk disease.
Why it matters
Potential benefit: If successful, patients with high-risk mantle cell lymphoma could gain new treatment options that exploit the tumor’s DNA repair vulnerabilities.
How similar studies have gone: Prior work has linked CCND1 overexpression to replication stress and repair pathway dependencies, suggesting potential for targeted therapies in this context.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Abeykoon, Jithma P — Mayo Clinic Rochester
- Study coordinator: Abeykoon, Jithma P
Related research
Other NIH-funded projects on the same topics.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
-
Understanding how certain cancers respond to Notch inhibitors
This study is looking into why some people with mantle cell lymphoma and chronic lymphocytic leukemia benefit from Notch inhibitors while others don’t, hoping to find clues in their genes that could help create better treatments for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.